Indian Nexavar compulsory licence case & the 100% test
This article was originally published in Scrip
Executive Summary
The Bombay High Court has, in an order against Bayer in the Nexavar (sorafenib tosylate) compulsory licensing case, underscored that for medicines, meeting "reasonable requirements" of the public to an "adequate extent" would mean 100% or to the fullest extent.